Here it is, hot off the pdf, and now you may be really confused, but that’s the nature of debate, and the Blog doesn’t (always) provide medical advice you should translate 1:1 into your own disease management, so take it with a pinch of salt and discuss your individual risk-benefit profile with your care team.ABN-Guidance-on-DMTs-for-MS-and-COVID19-APPROVED-11-March
Fortunately, those of you on immune reconstitution DMTs can rely on their long term effect with delaying re-dosing an obvious option in many cases, and those on a ‘treatment-escalation’ pathway (i.e. people on injectables, first line orals or fingolimod/siponimod) and those on natalizumab not being under immediate pressure to change, unless there are other factors (disease activity, JCV positivity, etc).
I also hear on the grapevine NHS eligibility criteria for natalizumab may temporarily be relaxed, so that this may be an option for people with highly active disease even if they don’t fulfill all ‘rapidly-evolving severe (RES)’ MS criteria.
There is also concern for pwMS and their respective care teams what to do about clinical trials in the current crisis. There is no blanket recommendation at this point in time, though the ABN position will no doubt be taken into consideration when looking at the timing of new starters & re-dosing.
CoI: Multiple due to speaking engagements & consultancy for pharma, and being chief investigator of ChariotMS.